Tagitol V

Tagitol V

Tagitol V Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Rarely, severe and occasionally fatal allergic reactions have been reported following administration of barium sulfate contrast agents. Such a reaction can occur up to 60 minutes following administration. Allergic reactions are more likely to occur in individuals with a history of allergic reactions to barium sulfate products.

Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. All of the allergic symptoms mentioned above can occur as either an immediate or delayed (up to 24 hours) reactions. Treatment should be initiated immediately with 0.3 to 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.

Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.

All E-Z-EM barium sulfate contrast and barium contrast delivery systems are latex-free.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


For use in opacifying residual stool in the colon in CT Colonography.


There is currently no drug history available for this drug.

Other Information

TAGITOL™ V is a barium sulfate suspension 40% w/v, 30% w/w for oral administration. Each 100 mL contains 40 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO4. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents.

Inactive Ingredients: artificial and natural apple flavor, carboxymethylcellulose sodium, citric acid, glycerin, maltodextrin, natural gum, polysorbate 80, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate and xylitol.

Tagitol V Manufacturers

  • E-z-em Canada Inc
    Tagitol V (Barium Sulfate) Suspension [E-z-em Canada Inc]

Login To Your Free Account